Real-World Use of Alirocumab: Experience from a Large Healthcare Provider

With the emerging use of anti-PCSK9 monoclonal antibodies for lowering low-density lipoprotein cholesterol (LDL-C) levels, real-world evidence (RWE) is needed to evaluate drug effectiveness. This study aimed to characterize new users of alirocumab and evaluate its effectiveness in achieving LDL-C ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Elis, Avishay, Melzer Cohen, Cheli, Chodick, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917622/
https://www.ncbi.nlm.nih.gov/pubmed/36769732
http://dx.doi.org/10.3390/jcm12031084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917622/
https://www.ncbi.nlm.nih.gov/pubmed/36769732
http://dx.doi.org/10.3390/jcm12031084

Ejemplares similares